Abstract
A 69-year-old male was transferred to our department by helicopter on a Sunday morning from the intensive care burn unit of another university hospital. In this unit, he had been treated for 3 days including a radical debridement of unattached skin. Before, he had been admitted in a dermatology department of another university hospital for exacerbated pemphigus vulgaris. Pemphigus had been diagnosed 2 years ago and treated with tapering doses of initially high-dose oral corticosteroids and mycophenolate mofetil before dramatic worsening of oral and skin lesions 3 months ago with a weight loss of 25 kg and generalized erosions and blistering. At the time of presentation in our clinic due to his poor general condition his only immunosuppressive medication was mycophenolate mofetil at a dose of 1 g/day.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rosenbach M, Murrell DF, Bystryn JC, Dulay S, Dick S, Fakharzadeh S, Hall R, Korman NJ, Lin J, Okawa J, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129:2404–10.
Zimmermann J, Bahmer F, Rose C, Zillikens D, Schmidt E. Clinical and immunopathological spectrum of paraneoplastic pemphigus. J Dtsch Dermatol Ges. 2010;8:598–605.
Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med. 2006;355:1800–10.
Schmidt E, Zillikens D. Modern diagnosis of autoimmune blistering skin diseases. Autoimmun Rev. 2010;10:84–9.
Kasperkiewicz M, Schmidt E, Zillikens D. Current therapy of the pemphigus group. Clin Dermatol. 2012;30:84–94.
Ahmed AR, Spigelman Z, Cavacini LA, Posner MR. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772–9.
Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol. 2010;38:186–95.
Joly P, Mouquet H, Roujeau JC, D’Incan M, Gilbert D, Jacquot S, Gougeon ML, Bedane C, Muller R, Dreno B, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545–52.
Kasperkiewicz M, Shimanovich I, Meier M, Schumacher N, Westermann L, Kramer J, Zillikens D, Schmidt E. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol. 2012;166:154–60.
Martin LK, Werth V, Villanueva E, Segall J, Murrell DF. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev. 2009;1:CD006263.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Schumacher, N., Mook, SC., Shimanovich, I., Zillikens, D., Schmidt, E. (2015). Life-Threatening Pemphigus Vulgaris. In: Murrell, D. (eds) Clinical Cases in Autoimmune Blistering Diseases. Clinical Cases in Dermatology, vol 5. Springer, Cham. https://doi.org/10.1007/978-3-319-10148-4_5
Download citation
DOI: https://doi.org/10.1007/978-3-319-10148-4_5
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-10147-7
Online ISBN: 978-3-319-10148-4
eBook Packages: MedicineMedicine (R0)